Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study-Reference-Cited by-同舟云学术

Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study

Published:2016-08 Issue:8 Volume:27 Page:1601-1606
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Suzuki K.,Yamanaka T.,Hashimoto H.,Shimada Y.,Arata K.,Matsui R.,Goto K.,Takiguchi T.,Ohyanagi F.,Kogure Y.,Nogami N.,Nakao M.,Takeda K.,Azuma K.,Nagase S.,Hayashi T.,Fujiwara K.,Shimada T.,Seki N.,Yamamoto N.

Funder

Pharma Valley Center

Shizuoka Organization of Creation Industries

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/27/8/1601/19446778/mdw220.pdf

Reference17 articles.

1. Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group.

2. Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group;Latreille;J Clin Oncol,1998